Jörg Stockhaus

Founder at conoGenetix biosciences GmbH

Consumer Services

Process Industries

Health Technology

Profile

Jörg Stockhaus is the founder of conoGenetix biosciences GmbH, which was founded in 2002, where he holds the title of Senior Scientist.
Currently, he is a Fellow at The Rockefeller University.
In the past, he held the position of Principal at Aventis Cropscience and Heinrich-Heine-Universität Düsseldorf.

Jörg Stockhaus active positions

Companies	Position	Start
conoGenetix biosciences GmbH conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany.	Founder	01/03/2002
The Rockefeller University	Corporate Officer/Principal	-

All active positions of Jörg Stockhaus

Former positions of Jörg Stockhaus

Companies	Position	End
Aventis Cropscience	Corporate Officer/Principal	-
Heinrich-Heine-Universität Düsseldorf	Corporate Officer/Principal	-

See the detail of Jörg Stockhaus's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jörg Stockhaus's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Aventis Cropscience	Process Industries
conoGenetix biosciences GmbH conoGenetix biosciences GmbH Pharmaceuticals: MajorHealth Technology conoGenetix biosciences GmbH develops peptide-based drugs and new ion channel selective drugs. It runs programs targeting severe autoimmune disorders like multiple sclerosis, rheumatoid arthritis, and vasculitis. The firm development pipeline encompasses peptide design, electrophysiology testing, biophysical parameters and synthesis, proliferation assays, and animal testing and toxicology. The company was founded by Andreas Klostermann, Mira Klostermann and Jörg Stockhaus in March 2002 and is headquartered in Planegg, Germany.	Health Technology